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Abstract
Background: Magnetic resonance high-intensity focused ultrasound (MR-HIFU) treatment for uterine fibroids is
rapidly gaining popularity as a treatment modality. This procedure is generally uncomfortable, painful, and requires
minimal or absence of movement and an MR-HIFU synchronised breathing pattern of the patient. Procedural
sedation and analgesia protocols have become the standard practice in interventional radiology departments
worldwide. The aim of this study was to explore if a sedation regimen with low-dose propofol and ketamine
performed by trained non-medical sedation practitioners could result in relief of discomfort for the patient and in
adequate working conditions for MR-HIFU treatment for uterine fibroids.
Methods: In this study, conducted from August 2013 until November 2014, 20 patients were subjected to MR-HIFU
treatment of uterine fibroids. Patients were deeply sedated using intravenous propofol and esketamine according to a
standardised hospital protocol to allow synchronisation of the breathing pattern to the MR-HIFU. The quality of sedation
for MR-HIFU and complications were recorded and analysed. The side effects of the sedation technique, the propofol and
esketamine consumption rate, the duration of recovery, and patient satisfaction after 24 h were examined.
Results: A total of 20 female patients (mean age 42.4 [range 32–53] years) were enrolled. Mean propofol/esketamine dose
was 1309 mg/39.5 mg (range 692–1970 mg/ 23.6–87.9 mg). Mean procedure time was 269 min (range 140–295 min).
Application of the sedation protocol resulted in a regular breathing pattern, which could be synchronised with the MR-
HIFU procedures without delay. The required treatment was completed in all cases. There were no major adverse events.
Hypoxemia (oxygen desaturation <92%) and hallucinations were not observed.
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Conclusions: The use of a specific combination of IV propofol and esketamine for procedural sedation and analgesia
reduced the discomfort and pain during MR-guided HIFU treatments of uterine fibroids. The resulting regular breathing
pattern allowed for easy synchronisation of the MR-HIFU procedure. Based on our results, esketamine and propofol
sedation performed by trained non-medical sedation practitioners is feasible and safe, has a low risk of major adverse
events, and has a short recovery time, avoiding a session of general anaesthesia.
Keywords: Deep propofol and esketamine sedation, Safety, MR-HIFU uterine fibroids treatment, Hallucinations and
sedation-related complications
Background
Procedural sedation and analgesia (PSA) has become
standard practice to achieve high-quality and efficient
conditions for uncomfortable and/or painful interven-
tion radiology procedures worldwide. Over the past de-
cades, the frequency of complex interventional radiology
procedures such as magnetic resonance high-intensity
focused ultrasound (MR-HIFU) has increased. The use
of MR-HIFU to treat tumours was first investigated in
1994 [1]. The development of MR-HIFU ablation is the
result of a search for less invasive treatments that can be
performed outside the operating room [2]. These treat-
ments are effective and less invasive when compared to
surgery, and are associated with less complication in
fibroid treatments [3–5]. MR-HIFU has been shown to
be an optimal modality for treating uterine fibroids
because of their good inherent tissue contrast [6], high
absorption of the ultrasound waves, and low blood flow
to most fibroids. During MR-HIFU treatments, ultra-
sound waves are focused in a focal point in the tumour
under MR-guidance, resulting in local temperature
elevations of at least 57–60 °C. Due to protein denatur-
ation at these elevated temperatures, subsequent tissue
necrosis occurs. MR-guidance is used for treatment
planning, for temperature measurements in the targeted
tissue, and for evaluation of treatment results. The MR-
HIFU patient table is integrated with a 1.5 Tesla MRI
scanner, forming a closed-loop feedback system. Because
of precise targeting guided by MR imaging, no damage
is caused to surrounding uterine tissue and other organs.
MR-HIFU is currently approved for the treatment of
uterine fibroids and under investigation for the treat-
ment of breast cancer, prostate cancer and brain lesions,
and pain palliation in bone metastases [7, 8]. During
MR-HIFU treatments, proton resonance frequency shift
(PRFS) MR thermometry is performed to monitor
temperature changes in the targeted and surrounding
tissue. However, the temperature monitoring based on
PRFS is very sensitive to patient motion and it may also
be affected by alterations of breathing patterns [9].
Because the size of each ablation is small (mm in diam-
eter) and cooling times between sonications need to be
applied, relatively long treatment durations are required
to ablate sufficiently large volumes of tumours cells,
making treatments uncomfortable for patients to sustain.
Moreover, these treatments may be painful in conscious
patients, resulting in discomfort, causing patients to
move. Synchronisation of the MR-HIFU treatment is
then impossible or the treatment even needs to be
aborted. Currently the efficacy and safety of HIFU treat-
ments of uterine fibroids is not widely accepted [10–12].
Female patients are increasingly seeking less invasive
treatment options than surgery, motivated by the in-
creased chances of fertility preservation and reduced
procedural recovery time. General anaesthesia or epi-
dural anaesthesia has often been used to provide optimal
treatment conditions for the radiologist and comfort to
the patient [13, 14]. Due the shortage of anaesthesiolo-
gists [15], new techniques, such as sedation, have been
developed to treat these patients. Sedation is performed
to prevent the patient from having MR-HIFU associated
deep visceral pain [16] and discomfort caused by “hot”
sensations on the skin. Uncontrolled sedation tech-
niques, using a combination of a hypnotic and an opioid,
are widely used but are commonly characterised by in-
stable breathing patterns due to variations in pain stim-
uli, hypnotic dosing, and duration of effects of short
acting opioids. An ideal sedation technique for MR-
HIFU treatment should result in an appropriate depres-
sion of the level of consciousness to enable patients to
undergo longer procedures (up to 270 min) in a stable
cardiovascular condition, with a regular and stable
breathing pattern in order to allow the MR signal to be
adequately synchronised with the HIFU signal and with
adequate analgesia. Propofol, 2,6-diisopropylphenol [17,
18] is an ultra-short acting hypnotic agent, which does
not provide any analgesia. Esketamine is a dissociative
anaesthetic providing sedation, analgesia, and amnesia.
In anaesthetic doses it may provoke hallucinations as
unwanted side effect. The unique catecholamine uptake
inhibiting properties cause a sympathomimetic effect
resulting in respiratory and cardiovascular stimulation
and stability. This is in contrast to other strong analgesic
drugs, which are associated with hypoventilation and
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hypotension. A combination of propofol and esketamine
has been documented and described in settings in emer-
gency department sedation and interventional radiology
[19–21]. We studied whether a moderate-to-deep sedation
technique based on a combination of low-dose propofol
and esketamine could provide acceptable and safe condi-
tions for MR-HIFU.
Methods
Study population and design
Twenty female patients were included in a pilot study to
evaluate the feasibility of moderate-to-deep sedation
using propofol and ketamine from August 2013 to No-
vember 2014 to provide suitable working conditions for
MR-HIFU ablation for uterine fibroids. Approval from
the Medical Ethical Committee (protocol number 13-
078/C) of the University Medical Center Utrecht was
obtained and the patients gave their informed consent.
The primary outcome was efficacy; the percentages of
patients in whom suitable working conditions allowing
adequate synchronisation of the breathing pattern with
the MR-HIFU targeting were achieved. Efficacy means
the creation of conditions necessary to safely facilitate
the completion of a procedure through attenuation of
pain, anxiety, and movement with amnesia or decreased
awareness [22]. The secondary outcomes were related to
patient sedation safety. The incidences of adverse events
were recorded as apnea, laryngospasm, hypotension,
bradycardia, and airway obstruction. A trained sedation
practitioner provided moderate-to-deep sedation as a sole
responsibility and was not involved in the procedure itself.
The medical condition of all patients was assessed accord-
ing to the hospital sedation screening protocol. Sedation
inclusion criteria used for selection of suitable patients
were age ≥18 years, American Society of Anesthesiologists
(ASA) I-III, and compliance with fasting policy guidelines
prior to procedure. Exclusion criteria: allergy against soy,
egg, peanuts, esketamine; the presence of metallic implants;
or other incompatibility with MRI (e.g. permanently im-
planted pacemakers). All procedures were executed in a
day case setting, where patients were discharged the same
day. The procedure time was defined as the period from
the start of procedural sedation and analgesia (PSA) until
the patient was awake, with circulatory and ventilatory pa-
rameters having returned to normal.
Preparation and treatment
An 18-gauge (1.3 × 48 mm) intravenous cannula was ap-
plied in each patient for continuous infusion of 0.9% saline
solution. Patients were pre-medicated with paracetamol
1000 mg, diclofenac 75 mg intravenously and oxycodone
5 mg orally, unless contraindicated. All patients were
positioned in the prone position. Patients’ vital signs were
continuously monitored (S/5™MRI compatible monitor
Datex-Ohmeda Finland) with a three-lead electrocardio-
gram (ECG), pulse oximetry (SpO2), non-invasive blood
pressure (NIBP) measurement measured at 5-min intervals
or more frequently when needed, and continuous
capnography (Smart CapnoLine Oridion Capnography Inc.,
Needham, MA). All patients received supplemental oxygen
(2 L/min) by nasal cannula. All data were electronically re-
corded (AnStat). Trained sedation practitioners provided
PSA, in accordance with a standardised protocol. Low-dose
propofol, 5 mg/kg/h (Propofol-Lipuro, Braun, Melsungen,
Germany) and esketamine 0.2 mg/kg/h (25 Multi-dose
Eurocept BV Ankeveen, the Netherlands) were adminis-
tered continuously with an infusion pump (Alaris Medical
UK Ltd., UK). Just before the start of the MR-HIFU
treatment, a single intravenous injection of esketamine
0.25 mg/kg was given. The sedatives were titrated such that
a continuous, regular breathing pattern was achieved, in
order to allow synchronisation with the MR-HIFU proced-
ure. Demographic details, propofol and esketamine admin-
istration, and procedure duration time were recorded. The
observer assessment of alertness/sedation (OAA/S) scores
were assessed and recorded every 10 min throughout the
procedure. OAA/S scores are based on a combination of
observations of the resting patient and patient responses to
verbal commands with increasing intensity and ranges from
1 (does not respond) to 5 (alert) [23].
Post-treatment follow-up
After the procedure, all patients were observed in the
recovery room for at least 1 h, using a minimum of
ECG, NIBP, and SPO2 monitoring. The modified Aldrete
[24] recovery score was recorded on arrival and every
10 min thereafter. Numeric rating pain scores were re-
corded and evaluated every 10 min with the use of a
visual analogue scale (VAS) 0–10 [25]. Patients were
discharged when full consciousness had been regained,
when the vital signs (heart rate, pulse oximetry, NIBP)
were at the baseline values, when the pain intensity VAS
was ≤3, and when the overall recovery (modified Aldrete
scale) scores were ≥9 and at least stable for a minimum
period of 60 min. Following discharge from the recovery
room, patients were transferred to the ward, where they
were further clinically observed for the next 3 h and
then discharged homewards. Discharge criteria required
that the patient was awake and alert with stable vital
signs, was able to ambulate without assistance and was
free of side effects of the drugs employed during the
procedure, and had a VAS ≤3 score. A patient’s clinical
outcome follow-up, according to the complication list of
the Dutch Society of Anaesthesiology (Additional file 1),
was analysed after 24 h, in which the patient completed a
questionnaire. The overall satisfaction was rated as never
again, insufficient, sufficient, good, or excellent. In addition,
pain, unwanted effects (headache, drowsy), complications,
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the incidence of hallucinations, and the speed of recovery
were assessed.
Complications
PSA-related complications during and after the procedure
were defined as severe for hypertension (the diastolic
blood pressure >110 mmHg and systole >180 mmHg, for
at least 5 min), or hypotension (defined as a mean blood
pressure of ≤60 mmHg for at least 5 min), for tachycardia
or bradycardia (increase or decrease in heart rate by 30%
from baseline, defined as a first measurement before any
change occurs), and for oxygen desaturation (SPO2 < 92%
for at least 5 min). Corrective measures were taken if
necessary at the discretion of the sedation practitioners. In
addition, upper airway obstruction/laryngospasm (defined
as an inspiratory stridor associated with a decrease in ar-
terial oxygen saturation), aspiration (defined as positive
when at the slightest clinical suspicion of aspiration a suc-
tion catheter was introduced in the trachea and fluid
could be aspirated), and nausea (secondary objectives)
were also recorded as a severe complication.
Statistical analysis
Statistical analysis was performed with IBM SPSS statis-
tics, version 23 software (SPSS INC, Chicago, IL). The
incidences of the primary outcome, as well as of adverse
events are reported as percentages (95% confidence
interval (CI)). The correlation between the treatment
duration and duration of sleep after the treatment was
analysed using linear regression analysis.
Results
Patient data
From August 2013 until November 2014, 20 patients re-
ceived a combined propofol/esketamine sedation according
to the protocol, for MR-guided high-intensity focused ultra-
sound (MR-HIFU) for uterine fibroids procedures. The pa-
tients were generally in good health: ASA I: eight patients
(40%) and ASA II: 12 patients (60%). Further patient’s
demographic data and characteristics are given in Table 1.
Primary outcome and safety
Our sedation procedure resulted in a stable spontaneously,
regular and effortless breathing pattern and in a relaxed,
non-moving patient, allowing excellent synchronisation of
the breathing pattern with the MR-HIFU procedure in all
patients (100%). The sedation technique with low-dose pro-
pofol and esketamine that was selected for this MR-HIFU
treatment resulted in stable hemodynamic and ventilatory
conditions, and no pain and discomfort to the patient dur-
ing this procedure. A stable breathing pattern proved to be
essential to allow an optimal synchronisation between the
continuous MR signal and the high-intensity ultrasound
targeting, which is vital for an optimal treatment. All thera-
peutic procedures could be finalised without interruption
due to faulty synchronisation of the MR signal and the
HIFU targeting. Sedation-related adverse events were not
reported during and after our treatments. The effects of
the sedation technique based on mean NIBP, heart rate,
SpO2, capnography, respiration rate, and OAA/S score are
depicted in Table 2. A regular breathing pattern was ob-
tained 5 min after the esketamine was administered. There
was no morbidity or mortality during and following the
MR-HIFU procedures. All patients recovered well and
were discharged the same day. All MR-HIFU treatment
procedures could be carried out efficiently and according
to plan. No hallucinations were observed and reported
during and after the treatment. In our study the patient
was relaxed, was not moving, and had no pain, thereby
allowing excellent synchronisation with a stable spontan-
eously regular and effortless breathing pattern during the
MR-HIFU procedure.
Recovery
All patients achieved the maximum Aldrete score of 10
points within the first 60 min, and the intensity of pain
(VAS score) after the procedure differed from patient to pa-
tient (Table 3). Eighteen out of 20 patients indicated a VAS
score of <3 within 30 min. After 60 min, one patient had
still a VAS 8 score (due to back pain) and a second one a
VAS 9 (due to skin burns). Both were successfully treated
with intra venous morphine. After 240 min all patients
could be discharged from the hospital with aVAS score ≤3.
Post-treatment evaluation
Fourteen patients rated the overall sedation satisfaction
for the MR-HIFU treatment as excellent, and six
patients rated the overall satisfaction as good. Fourteen
patients could resume their everyday activities within 2–
4 h, three patients within 6 h, two patients in less than
12 h, and one patient resumed her daily activities after
72 h following discharge from the hospital (Table 4).
Three patients indicated to have had a headache or
migraine-like headaches. Three patients were tired
following discharge and drowsy, and one patient noted
difficulty in passing stools for 24 h. In linear regression
analysis, a longer duration of the treatment in minutes
was associated with a shorter recovery time after the
treatment (R = 0.810, p < 0.001).







Mean 42.4 22.5 240.2 1308.8 42.3
Max 53 29.7 295 1970 87.9
Min 32 17.7 140 692 23.6
Age: in years
BMI body mass index: kg/m2, Min minutes, mg. milligram
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Discussion
MR-HIFU treatment of uterine fibroids is a promising
technique for treatment of uterine fibroids. The main
advantages, when compared to the conventional surgical
approach are that it is a non-invasive treatment allowing
quick recovery in day care, offering the advantage of an
increased likelihood to preserve fertility for a group of
young women. For an MR-HIFU treatment, which may
take up to 4 h or longer, to be successful, excellent work-
ing conditions are required. This means a patient lying
still during the whole procedure and a strictly regular
breathing pattern allowing optimal synchronisation be-
tween the continuous MR signal and the high-intensity fo-
cused ultrasound-targeting procedure. Previous attempts to
apply moderate-to-deep sedation using hypnotics and/or
opioids for this long lasting procedure, which is uncomfort-
able and often painful to undergo, have failed. The main
reason is a global shortage of trained medical sedation
practitioners and professionals, including anesthesiologist
to administer procedural sedation and analgesia [26–28].
The preferred method to allow this MR-HIFU procedure
is therefore general anaesthesia including muscular relax-
ation and artificial ventilation in most cases [29]. The pres-
ence of the pain, movements, and no regular breathing may
complicate the treatment procedure. The patient may not
be able to lie still for a prolonged period of time or
treatment-induced involuntary motion may occur if the
treatment is performed, while the patient is conscious.
Patient motion may hamper the MR images that are used
for treatment monitoring. In the present study, we report
the clinical observational study of the use of moderate-to-
deep sedation to allow MR-HIFU therapy directed at
ablating large volumes of uterine fibroids. Using a combined
technique with propofol and esketamine infusion, we
showed that moderate-to-deep sedation with this particular
technique resulted in regular breathing patterns and
adequate conditions to allow an undisrupted MR-HIFU
procedure for up to 270 min. The stable breathing pattern
allowed for an optimal synchronisation between the con-
tinuous MRI signal and the high-intensity focused ultra-
sound targeting in all patients, which is vital for an optimal
treatment. The technique also caused comfort to the patient
with a limited recovery time and good patient satisfaction.
Our study showed that ablation of uterine fibroids using
MR-HIFU with propofol/esketamine sedation was safe and
feasible without sedation-related adverse effects or compli-
cations that occurred during and/or after the treatment. In
other studies of sedation for HIFU treatment (with













1 min 50 112 79.9 94 100 98 4.5 6.0 5.2 10 20 14 79 112 98 5 5 5.0
30 min 54 102 73.2 96 100 98 4.6 5.8 5.4 9 18 14 71 110 86 3 4 3.8
60 min 56 100 72.4 95 99 97 4.5 6.2 5.5 9 20 14 62 105 79 2 5 3.1
90 min 50 90 71.0 94 99 97 4.5 6.2 5.7 8 20 13 62 90 74 2 4 2.6
120 min 54 92 71.7 94 99 97 4.9 6.3 5.8 8 24 15 64 94 79 2 4 2.5
150 min 50 96 71.7 94 100 97 5.0 6.2 5.7 8 24 15 62 102 81 2 3 2.5
180 min 48 92 71.4 94 100 97 4.4 6.1 5.6 8 25 15 68 95 80 2 3 2.6
210 min 50 90 72.0 95 100 97 4.9 6.1 5.5 8 24 14 68 94 84 2 4 2.8
240 min 54 90 72.0 96 100 98 5.0 5.9 5.5 9 24 15 67 99 85 2 4 3.1
270 min 54 88 77.2 96 100 98 5.3 5.9 5.5 12 18 14 80 101 87 3 5 4.0
Min minutes after start patient records registration, HR heart rate/minute, SpO2 saturation of peripheral oxygen in %, Capnography capnography in vol %, Resp.
rate respiratory rate/minute, Mean NIBP mean non-invasive blood pressure in mmHG, OAA/S observer’s assessment of alertness/sedation
Table 3 Patient VAS and Aldrete score
VAS score Aldrete score
N Min max mean Min max mean
After 10 min 20 0 8 0.7 6 10 8.35
After 30 min 20 0 8 1.15 8 10 9.65
After 60 min 20 0 7 1.15 9 10 9.8
After 240 min 20 0 3 0.6 9 10 9.85
VAS visual analogue scale score, N number of patients, Min minimum, Max
maximum, x min x minutes after the sedation
Table 4 Patient resumation of daily activities
Resumation daily
activities after x minutes
Patients (N) Percent (%) Cumulative
percent (%)
0 min N = 2 10 10
100 min N = 1 5 15
120 min N = 7 35 50
150 min N = 1 5 55
240 min N = 4 20 75
270 min N = 1 5 80
300 min N = 1 5 85
360 min N = 2 10 95
720 min N = 1 5 100
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midazolam and fentanyl) [30–32], the incidences of mild
and moderate pain in the abdomen were comparable to our
findings after the procedure. The level of safety achieved in
the present study may be the result of strict adherence to a
sedation protocol, careful patient selection and monitoring,
experience in the use of drugs, and extensive staff training.
Mortero et al. [33] confirms this in his study, where he com-
pared the effects of propofol and small-dose ketamine to
solely propofol, that a mixture of propofol and ketamine
provides an adequate and safe sedation and ventilation level
during monitored anaesthesia care, in elective ambulatory
surgery. Frizelle et al. [34] showed in his study that the side
effects of propofol during spinal anaesthesia could cause
dose-related cardiovascular and respiratory depression. The
addition of a small-dose ketamine infusion to propofol
increased hemodynamic stability, and less respiratory de-
pression, similar to our current finding. Frey et al. [35]
reviewed propofol esketamine published studies and con-
cluded that the combination of ketamine and propofol in
bolus form provides safer and more efficacious sedation,
with sufficient stability of vital signs. This is in accordance
with our findings. Twenty-four patients, who prefer treat-
ment without anaesthesia or sedation, by using low-dose
sonographically guided HIFU treatment, were alternatively
treated. Nevertheless, consequently mild pain, heat sensa-
tion, and discomfort occurred during and after the treat-
ment in the study of Cho and Leung [36]. Our results show
that we had fewer longer-term side effects than Fukunishi et
al. [37] reported. In his study, five (out of 20) patients took
longer than 3 days to return to their normal daily activity
and three patients experienced discomfort for more than
1 week due to mild buttock pain.
A possible disadvantage of performing HIFU treatments
under deep sedation is the patient’s disability to communi-
cate in case of pain or discomfort. This could lead to a
higher adverse event rate or even major complications. In
our study, redness of the skin was observed in several
patients after concluding the treatment and is due to accu-
mulative heating in the subcutaneous adipose tissue in spite
of long cooling times (2–10 min) in between consecutive
sonications. To resolve this issue and to shorten cooling
times, which in turn increases the efficiency of the treat-
ment and thereby the total treatment volume, a skin cool-
ing system was designed by Philips. This device was
integrated into the Sonalleve V2 HIFU-table and was tested
previously by our group with very promising results [38].
Careful treatment planning using anatomical MR images
and real-time MR thermometry prevented major adverse
events, such as sacral nerve damage.
This study had several limitations. The number of
recorded cases was relatively small, limited due to the ran-
domised study, and the population was treated in only a
single centre. Although the results of this study may help
to understand and manage similar clinical situations, any
attempt of other scenarios should be performed very care-
fully and confirmed in clinical studies. This sedation tech-
nique in combination with a HIFU treatment may create
new and innovative ways to treat patients with liver and
kidney tumours. Finally larger studies are necessary, for a
long-term evaluation of sedation-related outcomes, efficacy,
and side effects of esketamine and propofol sedation.
Conclusions
The use of a combination of propofol and esketamine for
procedural sedation and analgesia reduces the discomfort
and pain during MR-HIFU treatments of uterine fibroids
to an acceptable level according to the opinion of the
patients. This technique also caused cardiovascular and
respiratory stability and allowed easy synchronisation of
the breathing pattern with the MR-HIFU signal to provide
optimal treatment conditions for the interventional radi-
ologist. Based on our preliminary results, we consider our
esketamine and propofol sedation technique for MR-
HIFU treatment of uterine fibroids to allow optimal treat-
ment conditions, without major adverse events, to be safe
and efficient with a short recovery time for MR-HIFU
treatments of fibroid tumours. The technique may be con-
sidered as an acceptable alternative to general anaesthesia
with muscular relaxation and securing the airway with a
laryngeal mask or endotracheal tube.
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